Mariner
REGN icon

Mariner’s Regeneron Pharmaceuticals REGN Stock Holding History

Mariner’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95.7M Buy
123,954
+28,739
+30% +$22M 0.11% 158
2025
Q4 		$73.5M Buy
95,215
+63,275
+198% +$43M 0.09% 190
2025
Q3 		$18M Buy
31,940
+10,125
+46% +$5.72M 0.02% 450
2025
Q2 		$11.5M Buy
21,815
+9,174
+73% +$5.12M 0.02% 560
2025
Q1 		$8.02M Buy
12,641
+1,053
+9% +$724K 0.01% 631
2024
Q4 		$8.25M Sell
11,588
-140
-1% -$117K 0.01% 610
2024
Q3 		$12.3M Buy
11,728
+899
+8% +$1M 0.02% 479
2024
Q2 		$11.4M Sell
10,829
-129
-1% -$125K 0.02% 481
2024
Q1 		$10.5M Buy
10,958
+372
+4% +$354K 0.02% 498
2023
Q4 		$9.3M Buy
10,586
+3,068
+41% +$2.53M 0.02% 493
2023
Q3 		$6.19M Buy
7,518
+214
+3% +$168K 0.02% 577
2023
Q2 		$5.25M Buy
7,304
+220
+3% +$170K 0.01% 633
2023
Q1 		$5.82M Buy
7,084
+844
+14% +$637K 0.02% 583
2022
Q4 		$4.5M Buy
6,240
+325
+5% +$240K 0.01% 646
2022
Q3 		$4.08M Buy
+5,915
New +$3.72M 0.02% 567
2019
Q2 		– Sell
-857
Closed -$352K – 1142
2019
Q1 		$352K Buy
857
+134
+19% +$55.2K 0.01% 760
2018
Q4 		$270K Buy
+723
New +$265K ﹤0.01% 696

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Mariner's REGN Position: Q1 2026 in Review

Mariner increased its Regeneron Pharmaceuticals (REGN) stake by 30% in Q1 2026, buying an estimated $22M and bringing the position to 123,954 shares worth $95.7M. The position accounts for 0.11% of the portfolio, ranked #158.

Mariner first reported a position in REGN in Q4 2018 and has held it in 17 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Mariner held 123,954 shares of Regeneron Pharmaceuticals worth $95.7M as of Q1 2026.
  • Mariner bought 28,739 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $22M.
  • Regeneron Pharmaceuticals made up 0.11% of Mariner's portfolio in Q1 2026, its #158 holding.
  • Mariner first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 17 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.